Use of storage stable viscous phospholipid depot to treat wounds
BR112013002230A2
glatiramer acetate molecular weight markers
WO2007140287A2
Use of biomarkers of inflammation as indicators of drug efficacy
US2007116756A1
Stable pharmaceutical compositions
US2007004712A1
Salts of novel heterocyclic compounds having antibacterial activity
CA2617211A1
Amorphous aprepitant coprecipitates
NZ565831A
Preparation of amorphous montelukast using agitated thin film drying
CA2533038A1
Method of treatment for improved bioavailability
US2006194980A1
Process for the preparation of optically pure isomers of 2-(4-hydroxy phenoxy)-2-methyl-butyric acid methyl ester
CA2582449A1
Amorphous atorvastatin calcium
US2006004200A1
Processes to produce intermediates for rosuvastatin
US2006205766A1
Process for making crystalline form I of clopidogrel hydrogen sulphate
US2005171080A1
Polymorphs of ezetimibe and process for preparation thereof
EP1706394A1
Preparation of escitalopram
US2005234241A1
Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
BRPI0412557A
pharmaceutical dosage form of cardiovascular events
CN1835738A
Pharmaceutical compositions having a swellable coating
US2006004199A1
Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
US2005277693A1
Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
